within Pharmacolibrary.Drugs.ATC.L;

model L01EB07
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.8,
    Cl             = 0.0012016666666666666,
    adminDuration  = 600,
    adminMass      = 45 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 1.88,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.008566666666666667,
    Tlag           = 14.1,            
    Vdp             = 5.39,
    k12             = 2360,
    k21             = 2360
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>L01EB07</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Dacomitinib is an oral, irreversible second-generation tyrosine kinase inhibitor (TKI) targeting the epidermal growth factor receptor (EGFR). It is used for the treatment of non-small cell lung cancer (NSCLC) with EGFR-activating mutations. Dacomitinib is approved for clinical use.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters are based on adult patients with advanced solid tumors including NSCLC in multiple phase I trials.</p><h4>References</h4><ol><li><p>Piscitelli, J, et al., &amp; Tan, W (2022). The Effect of Hepatic Impairment on the Pharmacokinetics of Dacomitinib. <i>Clinical drug investigation</i> 42(3) 221–235. DOI:<a href=\"https://doi.org/10.1007/s40261-022-01125-x\">10.1007/s40261-022-01125-x</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/35195881/\">https://pubmed.ncbi.nlm.nih.gov/35195881</a></p></li><li><p>Ji, W, et al., &amp; Zhou, Q (2021). Effects of dacomitinib on the pharmacokinetics of poziotinib . <i>Pharmaceutical biology</i> 59(1) 457–464. DOI:<a href=\"https://doi.org/10.1080/13880209.2021.1914114\">10.1080/13880209.2021.1914114</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33899675/\">https://pubmed.ncbi.nlm.nih.gov/33899675</a></p></li><li><p>Rongala, DS, et al., &amp; Kunda, NK (2024). Oral inhalation of dacomitinib nanocarriers as a therapeutic strategy for non-small cell lung cancer. <i>Nanomedicine (London, England)</i> 19(18-20) 1601–1613. DOI:<a href=\"https://doi.org/10.1080/17435889.2024.2370225\">10.1080/17435889.2024.2370225</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/39073842/\">https://pubmed.ncbi.nlm.nih.gov/39073842</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end L01EB07;
